Author: Customer Service

– BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham  – Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma – Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers – Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma CHICAGO and FORT WORTH, Texas, June 09, 2026 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced that elraglusib will be evaluated in the BEACON2 clinical...

VenHub enters the Florida market through a new operator-led deployment model, marking a key step in its U.S. commercial rollout LAS VEGAS, June 09, 2026 (GLOBE NEWSWIRE) — VenHub Global, Inc. (NASDAQ: VHUB) (“VenHub” or the “Company”), a leader in fully autonomous Smart Store technology, today announced its expansion into the Florida market through a new commercial deployment with a local operator. The initial rollout will target the Tampa Bay region, representing VenHub’s first “Powered by VenHub” presence in the state. The expansion reflects VenHub’s broader commercial strategy of enabling local operators to deploy and brand autonomous retail locations using its fully integrated infrastructure platform, bringing enterprise-grade retail technology to high-traffic environments without the labor overhead, shrinkage exposure, or...

To Nasdaq Copenhagen A/S                                                                              June 9, 2026                                         Announcement No. 48/2026 Notice of Extraordinary General Meeting of Jyske Realkredit A/S on Thursday, June 25, 2026, at 7:30 a.m. at the company’s address: Kalvebod Brygge 3, 1560 Copenhagen V. Agenda for consideration and final adoption It is proposed that annual reports may be prepared in English, and accordingly, an amendment to the Articles of Association must be adopted pursuant to Art.100a of the Danish Companies Act if the general meeting approves the proposal.Proposed amendment to the Articles of Association: Art. 12, new (2): “Annual reports shall be prepared and presented in English. The Supervisory Board may determine that annual reports shall also be prepared in Danish.” Motion...

Sprouts Listing Gives GURU Nationwide Access to the U.S. Natural Channel’s Most Engaged, Health-Conscious Shopper MONTRÉAL, June 09, 2026 (GLOBE NEWSWIRE) — GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company“), Canada’s leading organic energy drink brand1, today announced the nationwide availability of GURU Lite and its four Zero Sugar flavors at Sprouts Farmers Market locations across the United States, effective June 22, 2026.GURU’s energy drink lineup offers a unique combination that the category rarely delivers at scale: organic ingredients, zero sugar, no sucralose, and no aspartame; a clean-label standard that speaks directly to the Sprouts shopper. The listing marks a significant milestone in GURU’s U.S. growth strategy, bringing its clean-label, organic lineup...

$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United States SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new $13.5 million financing for Angel Pharmaceuticals Ltd. (Angel Pharma), the Company’s collaboration partner in China. Corvus co-founded Angel Pharma in 2020 to enable the clinical development and commercialization of its pipeline in China as well as the development of other novel drugs. Corvus is Angel Pharma’s largest shareholder and is investing $5 million in the current financing. The funding is anticipated...

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed Phase 2 trial utilizes novel sequential treatment approach designed to combine rapid symptom control of FcRn inhibition with sustained disease modification of B-cell depletion therapy NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) (the “Company” or “TG Therapeutics”), today announced positive topline Phase 1 data for BRIUMVI in patients with myasthenia gravis (MG) and the initiation of a Phase 2 clinical trial evaluating BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with MG. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated,...

Competitive eating icon brings championship mindset to everyday wellness routines OMAHA, NE, June 09, 2026 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (Nasdaq: FTLF), a leader in innovative nutritional supplements and wellness products, today announced a new partnership between Dr. Tobias® and legendary competitive eater Joey Chestnut.  The campaign, built around the tagline “Cleanse Like a Winner,” brings together Chestnut’s championship mindset with Dr. Tobias’ focus on everyday wellness and digestive health support. The collaboration pairs one of the most recognizable names in sports entertainment with Dr. Tobias Colon 14 Day Cleanse in a campaign designed to inspire people to reset routines, stay consistent, and approach wellness with the mindset of a champion. Known worldwide for his record-breaking performances and larger-than-life...

WASHINGTON, June 09, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of former healthcare executive Sean O’Reilly as a Senior Managing Director in the firm’s Healthcare Risk Management & Advisory practice. Mr. O’Reilly brings more than 25 years of experience advising healthcare organizations on compliance program design, regulatory risk management and operational integrity across a range of healthcare sectors, including Medicare Advantage, Medicaid, employer group medical and specialty insurance, military healthcare, hospice, home health, value-based primary care and pharmacy. In his role at FTI Consulting, Mr. O’Reilly will advise clients on the design, implementation and improvement of enterprise compliance programs, focusing on risk identification, control development and regulatory...

MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Jared Oasheim, the Company’s Chief Financial Officer, will be stepping down from his role to pursue other professional opportunities. To support a seamless transition, Mr. Oasheim will remain with the Company until a successor is appointed and remain available as an advisor through February 2027. “Jared has been an integral part of CVRx since 2015, and has made a lasting mark on our company over the past decade” said Kevin Hykes, President and Chief Executive Officer of CVRx. “He led CVRx through its initial public offering and built the disciplined finance...

LOUISVILLE, Ky., June 09, 2026 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage, media and AdTech solutions, today announced that it will be added to the Russell 3000® Index effective when the US market opens on June 29, 2026, as part of the Russell indexes reconstitution. The June reconstitution captures up to the 4,000 largest US stocks as of April 30, ranked by total market capitalization. Membership in the Russell 3000® Index, which remains in place for half a year, also means automatic inclusion in the small-cap Russell 2000® Index as well as the appropriate growth and value-style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization...